).
Purpose:
To compare the diagnostic performances of contrast material-enhanced spectral mammography and breast magnetic resonance (MR) imaging in the detection of index and secondary cancers in women with newly diagnosed breast cancer by using histologic or imaging follow-up as the standard of reference.
Materials and Methods:
This institutional review board-approved, HIPAA-compliant, retrospective study included 52 women who underwent breast MR imaging and contrast-enhanced spectral mammography for newly diagnosed unilateral breast cancer between March 2014 and October 2015. Of those 52 patients, 46 were referred for contrast-enhanced spectral mammography and targeted ultrasonography because they had additional suspicious lesions at MR imaging. In six of the 52 patients, breast cancer had been diagnosed at an outside institution. These patients were referred for contrast-enhanced spectral mammography and targeted US as part of diagnostic imaging. Images from contrastenhanced spectral mammography were analyzed by two fellowship-trained breast imagers with 2.5 years of experience with contrast-enhanced spectral mammography. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value were calculated for both imaging modalities and compared by using the Bennett statistic.
Results:
Fifty-two women with 120 breast lesions were included for analysis ( , and fewer false-positive findings than MR imaging (five vs 45) (P , .001 for all results). In addition, contrastenhanced spectral mammography depicted 11 of the 11 secondary cancers (100%) and MR imaging depicted 10 (91%).
Conclusion:
Contrast-enhanced spectral mammography is potentially as sensitive as MR imaging in the evaluation of extent of disease in newly diagnosed breast cancer, with a higher PPV.
q RSNA, 2017 breast cancer between March 2014 and October 2015 (n = 120). Of these women, those who also underwent contrast-enhanced spectral mammography as part of clinical evaluation during this period were included for analysis (n = 52). Of those 52 patients, 46 were referred for contrastenhanced spectral mammography and targeted US as part of "second look" diagnostic imaging because they had additional suspicious lesions at MR imaging. In six of the 52 patients, breast cancer had been diagnosed at an outside institution and previously obtained images were not available. These patients were referred for contrast-enhanced spectral mammography and targeted US as part of diagnostic imaging. The 68 women who did not undergo contrast-enhanced spectral mammography were not referred by our breast imagers for the following reasons: MR imaging showed multicentric disease and/ or nipple involvement warranting mastectomy (n = 31); MR imaging did not show any additional suspicious lesions that precluded breast-conserving surgery (n = 23); US was more appropriate for further evaluation (eg, for morphologically abnormal axillary lymph nodes lesion morphologic features and perfusion characteristics while doing so at lower cost and with faster image acquisition, equal sensitivity in the detection of index cancers (8, 9) , and superior specificity (8) .
The purpose of this retrospective study was to compare the diagnostic performances of contrast-enhanced spectral mammography and MR imaging in the detection of index and secondary cancers in women with newly diagnosed breast cancer, with use of histologic or imaging follow-up as the standard of reference.
Materials and Methods
GE Healthcare (Chicago, Ill) provided the mammography unit used in this study. The authors had full control of the data and information presented for publication.
This retrospective study was approved by our institutional review board and compliant with the Health Insurance Portability and Accountability Act. The requirement to obtain informed consent was waived.
Patient Selection
The institutional picture archiving and communication system (Fujifilm, Stanford, Conn) was searched for all consecutive women who underwent contrast-enhanced breast MR imaging for the indication of newly diagnosed 
Abbreviations:
BI-RADS = Breast Imaging Reporting and Data System CNB = core-needle biopsy DCIS = ductal carcinoma in situ IDC = invasive ductal carcinoma NME = nonmass enhancement PPV = positive predictive value
Author contributions:
Guarantors of integrity of entire study, S.A.L.F., L.T., M.T., E.G., G.R.; study concepts/study design or data acquisition or data analysis/interpretation, all authors; manuscript drafting or manuscript revision for important intellectual content, all authors; manuscript final version approval, all authors; agrees to ensure any questions related to the work are appropriately resolved, all authors; literature research, S.A.L.F., L.T., M.T., A.R., E.G.; clinical studies, S.A.L.F., L.T., M.T., D.A.T., A.R., E.G., G.R.; statistical analysis, S.A.L.F., J.S.; and manuscript editing, all authors Conflicts of interest are listed at the end of this article. Breast MR imaging depicts both lesion morphologic features and perfusion characteristics related to neo-angiogenesis and is particularly sensitive for identifying multifocal (more than one cancer site within the same breast quadrant), multicentric (more than one cancer site within different breast quadrants), and contralateral disease (2, 3) . However, the specificity of MR imaging is limited, as both benign and malignant lesions can demonstrate enhancement (4). This limitation is potentially problematic for treatment planning, because additional suspicious enhancing lesions detected with MR imaging warrant targeted biopsy to confirm malignancy before any change in management, often resulting in delayed treatment (5) (6) (7) .
Advance in Knowledge
A few studies have evaluated bilateral contrast-enhanced spectral mammography as an alternative to MR imaging, citing its similar ability to depict Fourteen months after the end of the inclusion period, images from contrast-enhanced spectral mammography were evaluated independently by two of five breast imagers with 2.5 years of experience with contrast-enhanced spectral mammography. The readers had not seen the images previously and were aware that the population consisted of women with newly diagnosed breast cancer but were blinded to patient-specific demographic information, clinical history, and previous imaging results. Both low-energy and subtraction contrast-enhanced spectral mammographic images were evaluated. Radiologists identified suspected index cancers and suspected secondary cancers. They characterized each finding as a mass, NME, or focus; provided the maximum dimensions and locations; and described associated features (suspicious microcalcifications, architectural distortions, asymmetries, and/or biopsy micromarkers). Targeted US and/or biopsy was requested for further evaluation of secondary cancers. In one case with a discrepant interpretation, a third breast imager with 3 years of experience with pixel) at 90-second intervals following a 20-second delay after intravenous injection of 15 mL of gadolinium contrast agent (Magnevist; Bayer, Leverkusen, Germany) by using a power injector at a rate of 2 mL/sec, followed by a 20-mL saline flush. Postprocessing was completed with software (CADstream; Merge Healthcare, Chicago, Ill). Images were reviewed with the picture archiving and communication system and a dedicated workstation (CADstream, Merge Healthcare).
Contrast-enhanced spectral mammography.-Contrast-enhanced spectral mammography was performed with a dual-energy digital mammography unit with a flat-panel detector, cesium iodide absorber, field size of 19 3 23 cm, detector element pitch of 100 µm, and image matrix size of 1914 3 2294 (SenoBright, GE Healthcare). Tube voltage varied depending on breast density and thickness, ranging from approximately 26 to 30 kVp for low-energy images and from approximately 45 to 49 kVp for high-energy images, with exposure times ranging from approximately 4 to 10 seconds (8) .
Standard craniocaudal and mediolateral oblique mammographic projections of each breast were obtained at 90-second intervals after a 2-minute delay following intravenous injection of 90 mL of iodinated contrast material (Omnipaque 350, GE Healthcare) by using a power injector at a rate of 3 mL/sec followed by a 10-mL bolus of saline. The peripheral intravenous line was disconnected from the injector before image acquisition. High-and low-energy images of each projection were obtained and postprocessed automatically for subtraction images with the digital mammography unit. All projection images were obtained within 7 minutes. Mammography Quality Standards Act guidelines were followed in the performance of mammography. Images were reviewed at dedicated workstations (Hologic [Marlborough, Mass] and GE Healthcare).
Imaging Analysis
Clinical MR imaging reports were used. At our institution, all breast MR that would likely be located beyond the field of view of mammography) (n = 8); inflammatory breast cancer was present, necessitating neoadjuvant chemotherapy before consideration of breastconserving surgery (n = 2); previous contralateral mastectomy had been performed (n = 1); the patient had a history of allergy to contrast material (n = 1); and metformin had not been withheld on the day of contrast-enhanced spectral mammography (n = 1). In one case, contrast-enhanced spectral mammography was requested but not performed for unknown reasons.
Imaging Protocol MR imaging and contrast-enhanced spectral mammography were scheduled without consideration of timing relative to the menstrual cycle. MR imaging was performed before contrast-enhanced spectral mammography. In the 46 women who underwent second-look diagnostic imaging, contrast-enhanced spectral mammography and targeted US were performed during the same appointment.
MR imaging.-MR examinations were performed with patients in the prone position without breast compression by using a 1.5-T imaging unit (Avanto; Siemens, Erlangen, Germany) and a dedicated 16-channel breast coil. The following precontrast sequences were performed: axial T1-weighted imaging without fat saturation Correlation between Imaging and Histologic Findings When breast-conserving surgery was desired, additional suspicious MR imaging findings were pursued with contrast-enhanced spectral mammography and targeted US. If findings from contrast-enhanced spectral mammography and/or US confirmed the MR imaging finding as suspicious, targeted biopsy followed. If contrastenhanced spectral mammography and/or US revealed no correlate or a benign MR imaging finding (eg, complicated cyst), imaging follow-up ensued (MR imaging for MR imaging-only findings, and US for US correlates). Findings from MR imaging, contrast-enhanced spectral mammography, histologic examination, and imaging follow-up were recorded.
True-Positive, False-Positive, TrueNegative, and False-Negative Findings Cancer was defined as invasive carcinoma and ductal carcinoma in situ (DCIS). Noncancer was defined as benign and high-risk lesions, such as a fibroadenomas and atypical ductal hyperplasia, respectively. Cancers were counted as positive lesions, and noncancers were counted as negative lesions.
True-positive lesions were suspicious at MR imaging or contrast-enhanced spectral mammography and histologically proven to be cancers (Fig 1 ) . False-positive lesions were suspicious at MR imaging or contrast-enhanced spectral mammography and were histologically proven not to be cancer, had benign US correlates at follow-up US, or did not persist at follow-up imaging (Fig 2) . True-negative lesions were presumed noncancer lesions (eg, probable lymph nodes) at MR imaging and contrast-enhanced spectral mammography. False-negative lesions were defined as nondetected cancers.
Statistical Analysis
For overall cancer detection, sensitivity, specificity, positive predictive value 
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Results

Patient Demographics
Fifty-two women with 120 lesions were included for analysis (mean age, 50 years; range, 29-73 years). Eleven women had one lesion each, 19 had two lesions each, 17 had three lesions each, and five had four lesions each. None of the 52 women (0%) had a high-risk gene mutation such as BRCA. Four of the 52 women (8%) had a family history of breast cancer. Reasons for initial presentation included palpable breast abnormality (n = 26), abnormal screening mammogram (n = 18), breast cancer recently diagnosed at an outside institution (n = 6), and nipple discharge (n = 3). One woman presented with both a palpable breast abnormality and nipple discharge.
Diagnostic Imaging and Diagnosis
All women in the study population underwent digital diagnostic mammography with or without targeted breast US at our institution. The most common imaging abnormality was a suspicious mass. Forty-six of the 52 women (88%) underwent subsequent CNB for initial cancer diagnosis at our institution. A radiopaque micromarker was deployed after CNB in all cases (Table 1) .
Findings from MR Imaging and Contrastenhanced Spectral Mammography
Forty-seven of the 52 women (90%) underwent MR imaging before contrastenhanced spectral mammography. The mean interval between initial diagnostic imaging and MR imaging was 36 days, and the mean interval between MR imaging and contrast-enhanced spectral mammography was 23 days. No technical failures or adverse contrast material reactions occurred with either MR imaging or contrast-enhanced spectral mammography.
For index cancers, the most common MR imaging finding was a mass, and the most common contrast-enhanced spectral mammographic findings were mass enhancement and NME. The mean maximal dimension of index cancers was 31 mm. Additional (PPV), and negative predictive value were calculated with 95% confidence intervals for both imaging modalities and compared by using the Bennett statistic (McNemar test) for correlated proportions (10) . P , .05 was considered indicative of a significant difference. Statistical analyses were performed with software (Stata 13; StataCorp, College Station, Tex). False-positive findings.-The most common false-positive findings were a focus at MR imaging and NME at contrast-enhanced spectral mammography. There were 45 false-positive lesions with MR imaging, consisting of 11 high-risk lesions (five atypical ductal hyperplasias, one atypical lobular hyperplasia, one atypical papilloma, two papillomas, one lobular carcinoma in situ, and one flat epithelial atypia) and 11 benign lesions (three fibroadenomas, suspicious lesions were more often located in the contralateral breast at MR imaging (67%, 37 of 55 lesions) and in the ipsilateral breast at contrast-enhanced spectral mammography (69%, nine of 13 lesions). The most common additional suspicious lesion was a focus at MR imaging and NME at contrastenhanced spectral mammography. The mean maximal dimension of secondary lesions was 8 mm.
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Histologic Findings
Histologic findings were available in 94 of the 120 lesions (78%). Findings were based on US-guided CNB in 69 of the 94 lesions (73%), MR imaging-guided CNB in eight (9%), stereotactic CNB in six (6%), and surgical biopsy in 11 (12%). In 58 of the 94 lesions (62%), findings were based on both CNB and surgical histologic evaluation. In the remaining cases, 26 of the 120 lesions (22%) had imaging follow-up-18 (69%) for more than 2 years (American College of Radiology Breast Imaging Reporting and Data System [BI-RADS] category 2) and eight (31%) for less than 2 years (BI-RADS category 3).
Seventy-two of the 120 lesions (60%) were cancer, with 22 invasive ductal carcinomas (IDCs) with DCIS, 20 IDCs, 11 invasive lobular carcinomas, three invasive carcinomas of no special type, one invasive tubular carcinoma, and 15 DCISs.
Eleven of the 58 secondary lesions (19%) were cancer, with four IDCs with DCIS, four DCISs, and three invasive lobular carcinomas (Table 2 ).
Diagnostic Performances of MR Imaging and Contrast-enhanced Spectral Mammography
A per-lesion comparison of MR imaging, contrast-enhanced spectral mammography, and histologic or imaging follow-up is shown in Table 3 .
Overall performance.-The sensitivity, specificity, PPV, and negative predictive value of MR imaging and contrast-enhanced spectral mammography are shown in Table 4 . Contrastenhanced spectral mammography had a significantly lower sensitivity than Contrast-enhanced spectral mammography had significantly fewer falsepositive findings than did MR imaging (P , .001), with five false-positive lesions consisting of two fibroadenomas, one fibroadenomatoid change, and one complicated cyst diagnosed on the basis of four US-guided CNBs and one BI-RADS category 2 lesion with 27 months of imaging follow-up.
These false-positive lesions resulted in 21 additional CNBs, one surgical excisional biopsy, and 10 prophylactic contralateral mastectomies. The excisional biopsy and prophylactic contralateral mastectomies did not result in additional cancer diagnosis.
True-negative findings.-With MR imaging, two adjacent axillary tail masses were prospectively identified as lymph nodes, a finding corroborated with targeted second-look US. With contrast-enhanced spectral mammography, one mass was prospectively identified as a skin lesion, a finding corroborated by comparison with previous mammographic images with a mole marker.
Index cancers.-MR imaging enabled detection of all 61 index cancers (100%), and contrast-enhanced spectral mammography enabled detection of 58 (95%). The three undetected cancers are described previously in the section on false-negative findings.
Secondary cancers.-Of the 11 secondary cancers, eight (73%) were in the ipsilateral breast and three (27%) were in the contralateral breast. MR imaging enabled detection of 10 of
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Lee-Felker et al the 11 secondary cancers (91%) and did not reveal one case of ipsilateral DCIS (grade 1) measuring 20 mm, described previously in the section on false-negative findings. Contrastenhanced spectral mammography enabled detection of all 11 secondary cancers (100%).
Discussion
In our study, contrast-enhanced spectral mammography had a significantly higher PPV and fewer false-positive findings than did MR imaging for overall cancer detection. The detection of secondary cancers with contrast-enhanced spectral mammography was also similar to that with MR imaging.
Jochelson et al (8) found that contrast-enhanced spectral mammography had equal sensitivity to and higher specificity than MR imaging in the detection of index cancers, yet lower sensitivity in the detection of secondary cancers. In their study, both contrast-enhanced spectral mammography and MR imaging depicted 96% of index cancers, which is similar to our detection rate of 94%-99%. There was one false-negative finding each with contrast-enhanced spectral mammography and MR imaging, similar to our study. In addition, Jochelson et al had two false-positive lesions with contrastenhanced spectral mammography and 13 with MR imaging, similar to our study, with contrast-enhanced spectral mammography showing five false-positive lesions and MR imaging showing 45 false-positive lesions. However, they found 25 secondary cancers, whereas we found 11 secondary cancers. In addition, contrast-enhanced spectral mammography depicted 14 of 25 (56%) additional secondary cancers compared with 22 of 25 (88%) for MR imaging. Our detection rates for secondary cancers were similar between contrastenhanced spectral mammography and MR imaging. A possible explanation for these discrepancies in our findings is the different proportions of invasive cancers and DCIS in our study populations. DCIS comprised 2% (one of 52 lesions) of index cancers in the study by Jochelson et al but accounted for 21% (15 of 72 lesions) of our index cancers. Invasive carcinoma is more likely to be biologically aggressive compared with DCIS, which possibly accounts for increased secondary cancers in their study. Also of note, a quarter of their study population underwent MR imaging at outside institutions, with use of various MR imaging platforms and imaging protocols, and a prototype digital mammography unit was used to obtain contrast-enhanced spectral mammographic images. The reproducibility of their results is unclear in this context (8) .
Our study has a few potential limitations. Its retrospective design may have introduced a selection bias. Specifically, women with either obvious additional presumed disease or without additional suspicious lesions at MR imaging did not undergo contrast-enhanced spectral mammography and were not included in this study. The small study population and uncommon use of contrast-enhanced spectral mammography limit applicability of our results to the general population. The average interval between MR imaging and contrast-enhanced spectral mammography was 23 days and, when applicable, potential physiologic differences based on timing in the menstrual cycle may have affected perfusion characteristics and lesion conspicuity. In addition, the dose of intravenous contrast material for MR imaging and contrast-enhanced spectral mammography was not based on weight. True-negative lesions were defined as BI-RADS category 2 lesions only and did not incorporate BI-RADS category 1 breasts, which affected specificity and negative predictive value calculations, making comparison to other studies less straightforward. Potential cancers that were occult at imaging (mammography, US, contrastenhanced spectral mammography, and MR imaging) were unable to be detected, leading to an unknown number of false-negative lesions. Conversely, MR imaging and contrast-enhanced spectral mammography were performed after CNB in all cases, and the presence of biopsy micromarkers may have increased overall sensitivity for cancer detection. Multiple breast radiologists were involved in image analysis, which may have resulted in discrepant interpretations but is more representative of clinical practice. Imaging follow-up was somewhat limited. Finally, PPV is a suboptimal diagnostic measure owing to its dependence on disease prevalence.
Contrast-enhanced spectral mammography is a promising imaging modality, with the potential to depict lesion morphologic features and perfusion characteristics at lower cost, with faster imaging acquisition, and with similar sensitivity and superior PPV for overall cancer detection compared with MR imaging and with similar secondary cancer detection. Its limitations include relative contraindications in the setting of previous intravenous contrast material allergy and reduced glomerular filtration rate; use of radiation; scatter artifact, which limits evaluation of the peripheral breast tissue; and smaller field of view, which limits evaluation for suspicious axillary lymphadenopathy. However, we found that contrast-enhanced spectral mammography had similar sensitivity for index and secondary cancer detection, with superior PPV, compared with that of MR imaging. A follow-up study comparing MR imaging and contrast-enhanced spectral mammography in a broader sample of women with recently diagnosed breast cancer may be considered to validate these results, especially for secondary cancer detection.
In summary, contrast-enhanced spectral mammography can be integrated into routine diagnostic imaging and is valuable for the evaluation of extent of disease in women with newly diagnosed breast cancer. In addition, contrast-enhanced spectral mammography appears to represent an acceptable substitute for MR imaging in the setting of contraindications to MR imaging.
